Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

7 Bank Stocks Taking a Beating After SWIFT Joins Sanctions Against Russia

By Chris Lau, InvestorPlace Contributor

Some, but not all, bank stocks fell to bearish levels after SWIFT joined the punitive sanctions against Russian banks.

The Freefall in Moderna Stock Will End Eventually

By Chris Lau, InvestorPlace Contributor

The discount in MRNA stock will not last forever given Moderna's steady cash flow growth potential from its Covid-19 vaccine.

Why You Should Dump Lucid Stock While You Still Can

By Chris Lau, InvestorPlace Contributor

As the electric vehicle bubble pops, LCID stock is too risky to hold at the moment after the company lowered production forecasts for 2022.

Coupang’s Latest Results Show It’s a Long-Term Play for Patient Investors

By Chris Lau, InvestorPlace Contributor

CPNG stock price fell sharply after posting results, revealing details on Coupang's expenses and international expansion plans.

Alibaba Stock Is Trading at a Psychological Inflection Point

By Chris Lau, InvestorPlace Contributor

For the first time in more than five years, BABA stock is trading near $100 as it struggles to overcome slowing growth and rising competition.

Load More